Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2020-08-21 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于按期偿还2017年度第一期中期票据的自愿性信息披露公告
Capital/Financing Update Classification · 95% confidence The document is a voluntary disclosure announcement regarding the repayment of a medium-term note issued in 2017. It details the completion of full repayment of principal and interest for the debt instrument, including references to previous related announcements. The document is short (802 characters) and serves as an update on financing activities rather than a full financial report or audit. It does not contain financial statements or detailed financial analysis but focuses on capital repayment and financing status. Therefore, it fits best under Capital/Financing Update (CAP).
2020-08-21 Chinese
关于召开2020年第三次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2020 third extraordinary general meeting of shareholders for Shenzhen Haier Bioengineering Co., Ltd. It includes information about the meeting date, voting procedures, agenda items related to a non-public stock issuance, amendments to the company charter, and proxy voting instructions. The content focuses on notifying shareholders about the meeting and the proposals to be voted on, rather than presenting financial results or detailed financial statements. The document is not a report itself but an announcement of a shareholders meeting and related voting information. Therefore, it fits best into the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2020-08-20 Chinese
独立董事关于第八届董事局第十二次会议相关事项的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion from independent directors regarding specific corporate actions related to a non-public issuance of shares and the termination of a previous issuance plan. It references compliance with regulatory guidelines and company bylaws, and it discusses approval procedures and fairness of the transaction. The document is not a full financial report, earnings release, or management discussion, but rather a formal opinion on corporate governance matters related to capital raising and shareholder approval. It does not contain financial statements or detailed financial analysis. The document length is short (1186 characters), and it is a formal statement or opinion rather than a report or announcement of a report. This fits best under the category of Capital/Financing Update (CAP), as it deals with non-public issuance of shares and related corporate financing matters.
2020-08-07 Chinese
本次非公开发行股票摊薄即期回报对公司主要财务指标的影响及填补回报采取的措施的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Haiwang Bioengineering Co., Ltd. regarding a non-public issuance of shares and its impact on the company's key financial indicators, including dilution of immediate returns and measures to compensate for this dilution. It includes detailed financial assumptions, analysis of the impact on earnings per share and return on equity, risk warnings, and commitments by the board and controlling shareholders to uphold these measures. The document references regulatory guidelines from the China Securities Regulatory Commission and discusses capital raising, share issuance, and related financial management measures. It is not a full annual or interim financial report but rather a detailed update on a capital financing event and its financial implications. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (6057 characters) and content confirm it is a substantive announcement rather than a brief notice or a report publication announcement.
2020-08-07 Chinese
关于与深圳海王集团股份有限公司签署《深圳市海王生物工程股份有限公司与深圳海王集团股份有限公司之<非公开发行A股股票之股份认购合同>及<非公开发行A股股票之股份认购合同补充合同>之终止合同》的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the termination of a previously signed private placement subscription contract for A shares between Shenzhen Haier Bioengineering Co., Ltd. and its controlling shareholder Shenzhen Haier Group Co., Ltd. It details the termination agreement, confirms no disputes or debts remain, and states the effective date of termination. The document is short (1184 characters), formal, and focuses on a contract termination related to a capital raising activity (non-public issuance of shares). It does not contain financial statements or detailed financial data, nor is it a full report or presentation. It is an update on a financing-related contract termination, which fits best under Capital/Financing Update (CAP).
2020-08-07 Chinese
第八届监事会第六次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the sixth meeting of the eighth Supervisory Board of Shenzhen Haier Bioengineering Co., Ltd. It focuses on decisions related to the termination and new proposals for a non-public issuance of A-shares, including approval of related contracts, issuance details, pricing, lock-up periods, and authorization for the board to handle related matters. The document includes voting results and references to further shareholder meetings and regulatory approvals. It is not a financial report, earnings release, or audit report, but rather a formal announcement of board-level decisions and approvals regarding capital raising activities. This fits the definition of a Capital/Financing Update (CAP) filing, as it provides updates on company fundraising and capital structure changes.
2020-08-07 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.